Loading…
Loading…
IEIH (iShares Evolved U.S. Innovative Healthcare ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
The issuer typically closes a handful of funds during the month every year.
The pandemic-driven supply chain woes and the resultant red-hot inflation, the Russia-Ukraine war and the resultant hit to the commodity market as well as the central banks' policy tightening in the developed world may cause global growth slowdown in the coming days.
Uncertainties are playing a big role in the Wall Street due to record-high inflation, Fed policy tightening and Omicron strain of coronavirus. Still, some ETFs may warm up your winter portfolio.
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for IEIH and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.